BenevolentAI Investor Conference Presentation Deck

Poised for growth: multiple value inflection points Internal pipeline depth and progression AZ Collaboration Other Platform Collaborations H1 2023 BEN-2293: AD Data expected Q1 2023 BEN-8744: UC Begin Phase I study H1 2023 H2 2023 BEN-2293: AD Out-licensing BEN-28010: GBM Submit Clinical Trial Application (CTA) Expect to add 4-6 names drug programmes to portfolio 2024 BEN-8744: UC Phase I data package 2024, with Phase II to follow shortly after BEN-28010: GBM Initiate Phase I study Aim to progress 1-2 CTA/IND stage drug candidates every year Discussions with a number of parties ongoing Potential new targets added for SLE and Heart Failure - prior targets (3 for IPF and 2 for CKD) advancing Benevolent 28

View entire presentation